Fate Therapeutics Inc. (NASDAQ:FATE) – Stock analysts at Roth Capital issued their Q3 2016 earnings per share (EPS) estimates for shares of Fate Therapeutics in a research report issued on Thursday. Roth Capital analyst M. Breidenbach forecasts that the brokerage will post earnings of ($0.29) per share for the quarter. Roth Capital currently has a “Buy” rating and a $8.00 price target on the stock. Roth Capital also issued estimates for Fate Therapeutics’ Q4 2016 earnings at ($0.29) EPS, FY2016 earnings at ($1.17) EPS, Q1 2017 earnings at ($0.25) EPS, Q2 2017 earnings at ($0.26) EPS, Q3 2017 earnings at ($0.27) EPS, Q4 2017 earnings at ($0.28) EPS, FY2017 earnings at ($1.05) EPS, FY2018 earnings at ($1.08) EPS, FY2019 earnings at ($1.19) EPS and FY2020 earnings at ($0.45) EPS.
Fate Therapeutics (NASDAQ:FATE) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.03. The company had revenue of $1.03 million for the quarter, compared to analyst estimates of $1.02 million. Fate Therapeutics had a negative net margin of 699.10% and a negative return on equity of 90.94%.
A number of other research firms also recently commented on FATE. Zacks Investment Research raised Fate Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a research note on Thursday, August 11th. HC Wainwright reaffirmed a “buy” rating on shares of Fate Therapeutics in a research note on Tuesday, August 9th. BMO Capital Markets set a $4.00 price target on Fate Therapeutics and gave the company a “buy” rating in a research note on Monday, August 8th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $4.00 price target on shares of Fate Therapeutics in a research note on Tuesday, June 21st. Nine analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus target price of $6.54.
Fate Therapeutics (NASDAQ:FATE) opened at 3.44 on Monday. Fate Therapeutics has a 52 week low of $1.46 and a 52 week high of $6.71. The company’s market cap is $99.40 million. The stock has a 50 day moving average of $2.74 and a 200 day moving average of $2.05.
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Redmile Group LLC increased its position in shares of Fate Therapeutics by 1.0% in the second quarter. Redmile Group LLC now owns 1,502,180 shares of the biopharmaceutical company’s stock valued at $2,554,000 after buying an additional 15,200 shares during the last quarter. Lombard Odier Asset Management USA Corp boosted its stake in Fate Therapeutics by 2.8% in the second quarter. Lombard Odier Asset Management USA Corp now owns 256,426 shares of the biopharmaceutical company’s stock valued at $436,000 after buying an additional 7,052 shares during the period. Board of Trustees of The Leland Stanford Junior University purchased a new stake in Fate Therapeutics during the second quarter valued at $495,000. BlackRock Fund Advisors boosted its stake in Fate Therapeutics by 26.2% in the second quarter. BlackRock Fund Advisors now owns 75,572 shares of the biopharmaceutical company’s stock valued at $128,000 after buying an additional 15,701 shares during the period. Finally, Vanguard Group Inc. boosted its stake in Fate Therapeutics by 3.5% in the second quarter. Vanguard Group Inc. now owns 657,573 shares of the biopharmaceutical company’s stock valued at $1,118,000 after buying an additional 22,098 shares during the period. 48.71% of the stock is owned by hedge funds and other institutional investors.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.